Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study.

Hepatology (Baltimore, Md.) - 1 Sept 2024

Chung Sung Won, Moon Hye-Sung, Shin Hyunjae, Han Hyein, Park Sehoon, Cho Heejin, Park Jeayeon, Hur Moon Haeng, Park Min Kyung, Won Sung-Ho, Lee Yun Bin, Cho Eun Ju, Yu Su Jong, Kim Dong Ki, Yoon Jung-Hwan, Lee Jeong-Hoon, Kim Yoon Jun

Abstract excerpt

BACKGROUND AND AIMS: No medication has been found to reduce liver-related events. We evaluated the effect of sodium-glucose cotransporter-2 inhibitor (SGLT2i) on liver-related outcomes. APPROACH AND RESULTS: Single nucleotide polymorphisms associated with SGLT2 inhibition were identified, and a genetic risk score (GRS) was computed using the UK Biobank data (n=337,138). Two-sample Mendelian randomization (MR) was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Mellitus, Type 2

Share to Fatty Liver

Share to Liver Diseases

Share to Mendelian Randomization Analysis

Share to Polymorphism, Single Nucleotide

Share to Republic of Korea

Source

Identifiers

PMID: 38466796
DOI: 10.1097/HEP.0000000000000837

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study.PMID 38466796Read ↗

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity Read ↗

Association of SGLT-2 Inhibitors with Thyroid Dysfunction: A Drug-Target Mendelian Randomization StudySemantic proximity Read ↗

Mendelian randomization study of sodium-glucose cotransporter 2 inhibitors in cardiac and renal diseases.Semantic proximity Read ↗

SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study.Semantic proximity Read ↗

The effect of SGLT2 inhibition on immune cells and transplant rejection/failure: A drug-targeted mendelian randomization study.Semantic proximity Read ↗

Sodium-glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study.Semantic proximity Read ↗

CETP and SGLT2 inhibitor combination therapy improves glycemic controlSemantic proximity Read ↗

Pharmacological targets of SGLT2 inhibitors on IgA nephropathy and membranous nephropathy: a mendelian randomization studySemantic proximity Read ↗

Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes: An Umbrella ReviewSemantic proximity Read ↗

Genetic insights into SGLT2 inhibition and atrial fibrillation: exploring the mediating role of inflammatory proteins.Semantic proximity Read ↗

Assessment of the effect of the SLC5A2 gene on eGFR: a Mendelian randomization study of drug targets for the nephroprotective effect of sodium-glucose cotransporter protein 2 inhibition.Semantic proximity Read ↗

SGLT2 inhibition, circulating biomarkers, and Alzheimer's disease: A Mendelian randomization study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.